A to Z / Metabolic / weight loss

Tesofensine

Also known as NS2330.

Best known for The Alzheimer's candidate later studied for weight loss

Evidence★★★☆☆

Safety dataPoorly characterised

Route Oral

United StatesNot approved

AustraliaNot approved

as at 16 September 2026

What it is and what it does

Tesofensine is a small molecule triple monoamine reuptake inhibitor that has reached phase-2 trials for weight loss and is not approved. It is not a peptide. It appears in this book because it is often listed alongside peptides and discussed in the same weight-loss conversations.

What the full entry covers

The book carries the rest of this entry:

Where the research stands, with every claim cited
What people commonly ask, and what the research shows so far
Dosing in four labelled bands, described and not recommended
Side effects, serious risks, cautions and interactions
Questions to discuss with your doctor
How it compares with Semaglutide, 5-Amino-1MQ, AOD-9604

Related entries

SemaglutideThe drug that changed obesity treatment · Evidence ★★★★★
5-Amino-1MQAn oral compound studied for fat loss, often grouped with peptides · Evidence ★☆☆☆☆
AOD-9604The fat-loss peptide tested in a large phase 2b trial · Evidence ★★☆☆☆

A certificate of analysis tells you what is in a vial. The evidence rating above tells you whether the compound has been shown to work in humans. Neither answers the other's question. How to read a certificate of analysis.

This page describes what is known and not known about Tesofensine. It is not medical advice and not a recommendation to use it.